VistaGen Therapeutics(US:VTGN) TMX Newsfile·2026-02-16 14:50Core Viewpoint - Faruqi & Faruqi, LLP is investigating potential claims against Vistagen Therapeutics, Inc. due to allegations of securities law violations related to misleading statements about the company's clinical trial results for fasedienol, which led to significant financial losses for investors [2][4]. Group 1: Legal Investigation and Claims - The law firm is encouraging investors who purchased Vistagen securities between April 1, 2024, and December 16, 2025, to discuss their legal rights and options [1]. - A federal securities class action has been filed against Vistagen, with a deadline of March 16, 2026, for investors to seek the role of lead plaintiff [2]. - The complaint alleges that Vistagen and its executives made false and misleading statements regarding the likelihood of success in the PALISADE-3 clinical trial, which misled investors and inflated stock prices [4]. Group 2: Clinical Trial Results and Market Impact - On December 17, 2025, Vistagen announced that its PALISADE-3 study for fasedienol failed to meet its primary efficacy endpoint, resulting in an over 81% drop in stock price to $0.88 per share [5]. - The study did not show statistically significant improvement in reducing anxiety compared to placebo, which contradicted earlier positive assertions made by the company [4][5]. Group 3: Firm Background and Recovery - Faruqi & Faruqi, LLP is a prominent national securities law firm with a history of recovering hundreds of millions of dollars for investors since its establishment in 1995 [3].